IGF2BP1

Across TCGA pan-cancer cohorts, IGF2BP1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGF2BP1 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher IGF2BP1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated IGF2BP1 expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

ESCA, LGG, and COAD are the cancer types where IGF2BP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.506	0.358	.003	10	view →
LGG	DFS	Median	All	0.080	0.826	<.001	6	view →
COAD	DFS	Median	II,III,IV	0.230	0.654	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IGF2BP1–ESCA (DFS)

Open the ESCA breakdown →